FDA Approved a True Claim About Zyn — Then Let the Industry Aim It at Kids Who Never Smoked

In Jackson, Tennessee, there are more than twenty stores selling vape and nicotine pouches within a few miles of the public schools, in a state with no retail license requirement to stop any of them from selling to a kid who looks old enough. That’s not a hypothetical from a policy brief — it’s the count a local news report ran this week, the same week the FDA cleared four new flavored nicotine pouches for sale. Rich Berry. Cappuccino. Autumn Spice. Names built for a coffee shop menu, not a nicotine delivery device, landing on shelves those twenty-plus stores can put in front of anyone who walks in.

Zoom out to the federal level and the pattern gets starker. In June, the FDA authorized Swedish Match to market twenty ZYN pouch products with a specific sentence stamped on the science: using ZYN instead of cigarettes puts you at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. That claim is true. It’s also now legally printable on a product whose fastest-growing customer base never smoked a cigarette in their life.

Here’s Rize’s read, plainly:

A true claim about relative risk is not the same thing as a safe claim, and the FDA just handed the tobacco industry a sentence it will use to blur that line for fifteen years.

What actually got approved, in plain terms

A nicotine pouch is a small white packet — no tobacco leaf, no smoke, no chewing — that you tuck between your gum and lip. Nicotine absorbs straight through the gum tissue. No combustion means none of the roughly 7,000 chemicals that come off a burning cigarette, which is the whole reason the FDA’s own former tobacco chief, Mitch Zeller, calls pouches “demonstrably less harmful than burning tobacco leaves,” as he told NPR this month. That’s the plain-language version of what regulators mean by a “modified risk tobacco product,” or MRTP — FDA’s technical term for a product it has reviewed and agreed can be marketed with a specific, narrow, court-tested claim about being less harmful than a comparison product. Not risk-free. Not cessation-approved. Less harmful than smoking, for someone who was already smoking.

Stanford’s Bonnie Halpern-Felsher, who studies adolescent nicotine use, doesn’t dispute the underlying chemistry — she calls the harm-reduction potential for adult smokers “meaningful.” Her colleague Robert Jackler is blunter about what happens next: flavor names like “cool” and “smooth” position pouches “as a lifestyle enhancer,” he told NPR, not a medical off-ramp. Nobody serious argues Zyn is as dangerous as a Marlboro. The argument is about who’s buying it, and the label doesn’t discriminate between a fifty-year-old two-pack-a-day smoker trying to quit and a sixteen-year-old who’s never touched a cigarette.

We’ve run this exact play before

This isn’t the tobacco industry’s first “safer” claim, and the history is why regulators built the review process ZYN just passed. For decades, manufacturers sold “light” and “low tar” cigarettes on the implicit promise of reduced harm — lower numbers on a lab machine, marketed straight to smokers looking for permission to keep going. The promise was hollow: smokers compensated by inhaling harder and deeper, and the “light” descriptors delivered no real-world safety benefit while helping keep people smoking longer than they might have otherwise. When Congress passed the Family Smoking Prevention and Tobacco Control Act in 2009, it banned “light,” “low,” and “mild” outright and built the modified-risk pathway specifically so no company could make a reduced-harm claim again without FDA proving the science first. ZYN’s claim is the system working as designed — vetted, narrow, evidence-based. The open question, the one the 2009 law couldn’t fully close, is whether a true claim can still be marketed in a way that recruits new nicotine users rather than converting existing ones.

The numbers say it’s already happening

The CDC Foundation’s TEEN+ study, a longitudinal survey of more than 10,000 young people, found pouch use among youth and young adults nearly quadrupled between 2022 and 2025, and nicotine pouches are now the second most common tobacco product among youth, trailing only vapes. Monthly sales industry-wide surged 250.8% between January 2023 and August 2025. Nearly two in five youth and young-adult users are using pouches more than five days a month — this isn’t experimentation, it’s a habit forming. Zyn alone accounts for 84% of past-month pouch use among that group. The American Heart Association put it flatly this month: flavored authorizations threaten to sustain youth nicotine use, full stop, no hedge.

Nearly two in five youth and young-adult users are using pouches more than five days a month — this isn’t experimentation, it’s a habit forming.

Meanwhile the FDA’s enforcement posture is moving the other direction. A May guidance lowered the enforcement priority for e-cigarettes and pouches sold without full premarket authorization while applications sit in a backlog — a policy STAT News reported health groups are now suing to overturn, with one expert calling it a “get out of jail free card” for manufacturers already on shelves illegally. You can authorize the true claim and starve the enforcement that would keep it in its lane. Right now, that’s what’s happening simultaneously.

If you’re the one holding the can

If you’re an adult smoker and pouches got you off cigarettes, Rize isn’t here to shame you — the chemistry backs you up, and switching entirely away from combustion is a real reduction in your own risk. But if you started on pouches and never smoked, that risk-reduction math doesn’t apply to you at all; you’re not comparing pouches to cigarettes, you’re comparing pouches to nothing, and nicotine is nicotine — addictive on its own terms, tied to elevated heart rate and blood pressure, and, per Halpern-Felsher, still carrying open questions about long-term cardiovascular and dental effects nobody’s tracked at scale yet. If mint or citrus pouches have become a five-times-a-week habit and you didn’t mean for that to happen, that’s worth naming honestly, to yourself first.

There’s real pharmacology in the pipeline built for exactly this. A plant-derived compound that latches onto the same brain receptors nicotine does, so cravings quiet down without the addictive hit — that’s cytisinicline, and it would be the first new FDA-approved quit-smoking medication in twenty years if it clears the agency’s remaining manufacturing review, after Achieve Life Sciences disclosed a Complete Response Letter in June tied to a third-party manufacturing inspection, not to safety or efficacy findings — and it’s also been fast-tracked as a vaping-cessation aid. That’s still pending. What’s not pending, right now, today, if you’re in Arizona: ASHLine at 1-800-55-66-222 gives you free coaching and free nicotine replacement therapy, no insurance required, with programs built specifically for teens and young adults who started on pouches or vapes rather than cigarettes.

Arizona is at least trying to close the gap the FDA won’t

Arizona didn’t wait on Washington. A law signed this June requires state licensing for alternative-nicotine distributors for the first time, bans packaging designed to appeal to minors — no cartoon characters, no game-styled tins — and imposes $10,000 fines with license suspension for retailers caught repeatedly selling to anyone under 21. It’s a state closing a gap the federal enforcement retreat opened. More on where policy and funding fights over nicotine are heading, and the full nicotine and tobacco archive, are both live on the site.

The fine print nobody reads before the pouch is already under their lip

Every can of Zyn now carries a sentence the FDA fought a legal battle to make true and specific. Nobody fought a battle to make sure the can only reaches the smoker it was written for. That gap — between what’s legally defensible and who’s actually reaching for the tin at the gas station counter — isn’t a footnote to this story. It’s the whole story.